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Homologous recombination deficiency (HRD) is a defining characteristic in BRCA-deficient
breast tumors caused by genetic or epigenetic alterations in key pathway genes. We
investigated the frequency of BRCA1 promoter hypermethylation in 237 triple-negative breast
cancers (TNBCs) from a population-based study using reported whole genome and RNA
sequencing data, complemented with analyses of genetic, epigenetic, transcriptomic and
immune infiltration phenotypes. We demonstrate that BRCA1 promoter hypermethylation is
twice as frequent as BRCA1 pathogenic variants in early-stage TNBC and that hypermethy-
lated and mutated cases have similarly improved prognosis after adjuvant chemotherapy.
BRCA1 hypermethylation confers an HRD, immune cell type, genome-wide DNA methylation,
and transcriptional phenotype similar to TNBC tumors with BRCA1-inactivating variants, and it
can be observed in matched peripheral blood of patients with tumor hypermethylation.
Hypermethylation may be an early event in tumor development that progress along a
common pathway with BRCA1-mutated disease, representing a promising DNA-based bio-
marker for early-stage TNBC.
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Triple-negative breast cancer (TNBC) encompasses a sub-group of tumors defined by absence of estrogen and pro-gesterone receptor expression and lack of amplification of
the human epidermal receptor growth factor 2/erythroblastic
oncogene B (HER2/ERBB2) gene. TNBCs comprise ~10% of all
breast cancers and are clinically aggressive with an often poor
prognosis, partly due to the lack of targeted therapeutics.
Although being classified as a clinical tumor entity, TNBC tumors
display a high degree of molecular heterogeneity. TNBC tumors
are associated with pathogenic variants in the BRCA1 breast
cancer susceptibility gene, with 7–20% of diagnosed patients
harboring pathogenic germline or somatic variants1–4. The
BRCA1 protein has multiple distinct roles in maintaining genome
integrity, particularly, through homologous recombination (HR)-
mediated double strand break repair5. Tumor cells deficient for
BRCA1 (or BRCA2) are considered HR-deficient (HRD) and
sensitive to cytotoxic agents and poly (ADP-ribose) polymerase
(PARP) inhibitors, which cause DNA damage or increased
demand for double strand break repair6. The HRD phenotype is
utilized in promising clinical studies of germline BRCA1/BRCA2-
mutated breast or ovarian cancer3,7,8. In addition, BRCA1/
BRCA2-mutated breast cancers have been suggested to be more
immunogenic than non-HR defective tumors9–11. The increase in
immunogenicity may be related to better responses to checkpoint
blockade response, although this remains to be proven.
Between 40% and 70% of TNBC tumors are reported to have a
presumed HRD phenotype, which exceeds the number of cases
with germline/somatic BRCA1/BRCA2 inactivating variants3,12,13.
This suggests that other mechanisms and/or genes may confer a
similar phenotype. DNA promoter hypermethylation could be an
alternative mechanism of inactivating BRCA1. BRCA1 promoter
hypermethylation has been reported in 16–57% of TNBCs across
studies14–20, superseding the frequency of germline BRCA1
alterations, however, with conflicting reports about association
with prognosis (e.g. refs. 14–16,18,21). Currently, we lack a detailed
multi-layer comparison of BRCA1 hypermethylated versus
BRCA1-mutated early stage TNBCs using current state-of-the-art
profiling techniques that thoroughly investigates similarities and
differences between the two groups.
In the current study, we pursued the hypothesis that BRCA1
promoter hypermethylation confers an omics phenotype identical
to that of BRCA1-mutated TNBCs, and that the two entities have
equivalent patient outcomes in response to standard of care
chemotherapy. To this end, we analyzed a recently reported
unselected population-based cohort of 237 early stage TNBC
tumors profiled by comprehensive whole-genome sequencing
(WGS), RNA sequencing, global DNA methylation analysis22,
further complemented with 54 additional BRCA1-mutated
tumors from previous studies23,24. Herein, we sought the fre-
quency of BRCA1 promoter hypermethylation, its tumor phe-
notype compared to tumors with BRCA1 inactivating genetic
variants (somatic or germline, BRCA1-null), and its association
with clinicopathological variables, molecular subtypes, and
patient outcomes in early-stage TNBC. We demonstrate that
BRCA1 hypermethylation is twice as frequent as BRCA1-null
tumors in early-stage unselected TNBC and that elevated BRCA1
promoter methylation is detectable in peripheral blood DNA of
patients with hypermethylation in the tumor. Moreover, we show
that in terms of mutational, epigenetic, transcriptional, and
immune infiltration profiles, BRCA1 hypermethylation confers a
tumor phenotype practically identical to that of BRCA1-null
cases. BRCA1 hypermethylation and BRCA1 mutation are equally
associated with better outcome after adjuvant chemotherapy
when compared to TNBC patients without BRCA1 inactivation,
thus BRCA1 hypermethylation represents a promising DNA-
based prognostic marker.
Results
BRCA1 mutations and promoter hypermethylation in TNBC.
Table 1, Fig. 1, and Supplementary Fig. 1 outlines patient
demographics, selection, and study layout. The original 237
TNBC patients (hereinafter referred to as the SCAN-B cohort)
reported by Staaf et al.22 represent 58% of the total number of
diagnosed TNBC cases in the studied healthcare region during
the inclusion period (September 1 2010 to March 31, 2015), and
has been shown to be representative of the total regional popu-
lation with respect to key clinicopathological variables. Of these
patients, 24.1% (57/237) were classified as BRCA1 promoter
hypermethylated based on pyrosequencing, while 25 were
BRCA1-null cases of which 19 carried germline variants and six
somatic variants (Supplementary Data 1). Similar hypermethy-
lation rates were observed across different years of diagnosis in
the SCAN-B cohort: 21.0% hypermethylated cases diagnosed
2011, 22.2% in 2012, 26.4% in 2013, and 21.7% in 2014. Pyr-
osequencing classifications were corroborated by Illumina DNA
methylation profiling data for BRCA1 gene associated CpGs
(Fig. 2a), and markedly reduced BRCA1 mRNA expression from
RNA sequencing for hypermethylated cases (Fig. 2b), similar to
previous reports25, that were in line with expression levels for
cases with BRCA1 frame shift, nonsense and indel variants
(Supplementary Fig. 2). Of the 57 hypermethylated cases, 51
(89.5%) showed concurrent LOH of BRCA1 (tumor cell content
by WGS range 23–82%) with the six remaining cases having low
estimated tumor cell content (between 11% and 23% by WGS),
Table 1 Clinicopathological characteristics of SCAN-B TNBC
patients.
BRCA1
hypermethylated
BRCA1-nulla non-BRCA1
N 57 25 155
Age
<35 years 14.0% 28.0% 0.6%
35–50 years 28.1% 12.0% 11.0%
50–70 years 47.4% 52.0% 43.9%
≥70 years 10.5% 8.0% 44.5%
Germline BRCA1
variantb
0% 76% 0%
Tumor size
≤20mm 57.9% 52.0% 47.7%
>20mm 42.1% 48.0% 52.3%
Nodal status
Node negative 70.2% 48.0% 65.2%
Node positive 28.1% 48.0% 34.2%
Missing data 1.8% 4.0% 0.6%
Tumor grade
Grade 2 0% 0% 18.1%
Grade 3 98.2% 96.0% 80.0%
Missing data 1.8% 4.0% 1.9%
ER-staining positivityc
<1% 89.5% 84.0% 87.6%
1–10% 10.5% 16.0% 12.4%
Therapyd
Chemotherapy 87.5% 91.7% 66.9%
Untreated 12.5% 8.3% 33.1%
IDFS evente 17.5% 28.0% 38.7%
Median IDFS for
patients (years)f
5.0 (0.1–7.1) 4.8 (0.2–6.7) 4.6 (0.6–7.2)
DRFI evente 10.5% 20.0% 24.5%
Median DRFI for
patients (years)f
4.6 (0.1–7) 4.1
(0.05–6.6)
4.3 (0.4–7.2)
Death eventE 14.0% 24.0% 31.6%
Median OS for
patients (years)f
4.7 (0.2–7.1) 4.1 (2.9–6.8) 4.6 (2.7–7.1)
Data obtained from the Swedish national breast cancer quality registry. Cases with missing data
omitted from calculations if not shown as separate variable.
aBRCA1-null includes cases with both germline and somatic BRCA1 inactivating genetic variants.
bBased on whole genome sequencing data.
cIn Sweden, ER-negativity is defined as ≤10% of cells with IHC-staining for ER.
dIncludes all cases irrespective if eligible for outcome analysis, but excluding cases with
palliative treatment.
eIncludes all events, irrespective of eligibility for outcome analysis.
fTime and range for patients without an event, irrespective of eligibility for outcome analysis.
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which possibly interfered with the copy number analysis. In
comparison, 84% of BRCA1 germline cases showed LOH of the
wild-type allele, again with low associated tumor cell content for
cases without LOH (n= 3, 11%, 18%, and 27% by WGS). Fur-
thermore, BRCA1 hypermethylated and BRCA1 germline muta-
ted cases without BRCA1 LOH had similar proportions of
rearrangement signature 3 and deletions with microhomology,
representing prototypical signatures of BRCA1-deficient cancer24
(Fig. 2c). This suggests that BRCA1 hypermethylation or BRCA1
germline alteration without concurrent LOH is rare in early-stage
TNBC specimens and when observed may be due to tissue
sampling limitations. Consistent with Fig. 2c, HRD classification
from the previous report22 revealed that 98.2% (56/57) of
hypermethylated cases were called as HR deficient by two dif-
ferent HRD algorithms13,26. Presence of nonmalignant cells in
tumors may skew analyses of genomic data obtained from bulk
tumor analyses (such as RNA sequencing and DNA methylation).
In the SCAN-B cohort, there was no statistical difference in
tumor cell content estimated by WGS between hypermethylated
and BRCA1-null cases (t-test, p= 0.47), suggesting that non-
malignant infiltration should not affect group-level conclusions.
Tumor cell content showed a strong linear correlation with
BRCA1 CpG allele methylation rate for hypermethylated cases
when using WGS specific estimates also accounting for possible
subclonality (r2= 0.84, slope= 0.90, Fig. 2d).
Overall, BRCA1 hypermethylation was 2.3 times more frequent
than BRCA1-null cases, and three times more frequent than
BRCA1 germline alterations. In the SCAN-B cohort, BRCA1
hypermethylation was mutually exclusive with BRCA1-null cases
and BRCA2 tumors with only one exception. One of the ten
BRCA2-null SCAN-B cases displayed BRCA1 hypermethylation.
This case, PD35990a, showed a pathogenic biallelic BRCA2
variant (p.Pro3194Asnfs*2 germline mutation and BRCA2 LOH)
and distinct BRCA1 hypermethylation (61% CpG allele methyla-
tion) together with BRCA1 LOH. The tumor had genomic
patterns of Substitution Signature 3, Rearrangement Signatures 2
and 3 and loss of BRCA1 gene expression, all characteristic of
BRCA1- but not BRCA2-deficient tumors24,27 (Fig. 2e).
Elevated BRCA1 promoter hypermethylation in peripheral
blood. Forty-six of the 237 SCAN-B patients underwent clinical
BRCA1/2 germline screening due to family history and/or young
age at diagnosis according to Swedish guidelines. Nine cases
showed germline inactivating BRCA1 variants and three had
germline inactivating BRCA2 variants. Among the clinically
screened patients without a pathogenic germline BRCA1/BRCA2
variant, 16 out of 34 (47.1%) displayed tumor BRCA1 hyper-
methylation while 18 did not. Patients with BRCA1 hyper-
methylated tumors were significantly younger at diagnosis
compared to the patients negative for both tumor methylation
and BRCA1/2 loss of function variants (median age 36 versus 50
years, t-test, p= 8e−5). In fact, age at diagnosis for hyper-
methylated patients was similar to patients with pathogenic
germline BRCA1 variants (median age 36 versus 32 years, t-test,
p= 0.82) (Fig. 3a). Based on oncogenetic counseling data, only
one of the 16 BRCA1 hypermethylated patients had a first-degree
relative with breast/ovarian cancer, indicating that these TNBC
patients had likely been referred for screening based on young age
rather than family history. SCAN-B patients with BRCA1
hypermethylated tumors (n= 16) also showed higher levels of
BRCA1 promoter methylation in matched peripheral blood DNA
than the 18 patients with unmethylated tumors and no BRCA1/2
variants (hypermethylated: n= 16, mean CpG allele frequency=
4.03, median= 3.5, sd= 1.53; unmethylated: n= 18, mean=
3.03, median= 3.0, sd= 0.61; t-test p= 0.024, Wilcoxon’s test,
p= 0.015, Fig. 3b). Trends also remained significant after trans-
formation of pyrosequencing methylation rates to M-values
(t-test, p= 0.02).
To confirm these findings, we analyzed peripheral blood DNA
from 71 additional SCAN-B cases from our cohort not subjected
237-sample
SCAN-B cohort
described in Staaf et al.
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Fig. 1 Study scheme, performed analyses, and cohorts used. Gray boxes indicate a cohort of samples.
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to prior clinical screening, including 39 cases with tumor BRCA1
hypermethylation and 32 without. Again, higher BRCA1
promoter methylation levels were found in blood DNA from
patients with BRCA1 tumor hypermethylation (t-test, p= 0.005,
Wilcoxon’s test, p= 0.01). The finding remained significant after
transformation of methylation rates to M-values (t-test, p=
0.006, Wilcoxon’s test, p= 0.01). When we combined both
clinically screened and unscreened SCAN-B patients (n= 105 in
total, reanalyzed using the same instrument settings and reagent
lots), we observed that the higher BRCA1 blood DNA methyla-
tion levels appeared independent of age (two-way ANOVA
interaction model with tumor hypermethylation status and age
groups, p= 0.002, Fig. 3c). This finding remained significant after
transformation of methylation rates to M-values (two-way
ANOVA interaction model with tumor hypermethylation status
and age groups, p= 0.002).
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Clinical and genomic features of BRCA1 methylated TNBC.
BRCA1 promoter hypermethylation and BRCA1-null frequencies
in subgroups of SCAN-B TNBC patients defined by clin-
icopathological variables and molecular subtypes are shown in
Table 2. Hypermethylation frequency was especially high in
patients under 50 years (46.2% frequency, Fisher’s exact test, p=
8e−5). A trend of lower age at diagnosis for hereditary BRCA1
cases, followed by BRCA1 hypermethylated cases, BRCA1/BRCA2
somatic cases, and non-altered cases was observed in the total
SCAN-B cohort (Fig. 3d).
Several gene expression based subtyping schemes have been
proposed in breast cancer (e.g., the general PAM5028, CIT29, and
IntClust 1030 as well as TNBC specific subtypes31). In all
instances, BRCA1 hypermethylation was strongly associated with
the proposed basal-like phenotype (PAM50 basal-like p= 2e−5,
CIT basal-like p= 1e−6, TNBCtype BL1 p= 0.02, and IntClust
10 cluster 10 p= 4e−6, Fisher’s exact test performed in a 2 × 2
basal-like vs. non-basal context) (Table 2 and Fig. 3e). The
subtype proportions for BRCA1-null and non-BRCA1 altered
cases are shown in Supplementary Fig. 3, demonstrating
similarity between hypermethylated and BRCA1-null cases.
BRCA1 hypermethylation was also observed in clinicopatho-
logical and molecular subgroups not commonly associated with
BRCA1-deficiency, including old patients, tumors with some ER
staining (1–10% by immunohistochemistry), and in non-basal
like gene expression subtypes, although at low relative frequencies
similar to those observed in BRCA1-null cases (Table 2).
BRCA1 hypermethylation and patient outcome in TNBC.
Association of BRCA1 promoter hypermethylation status with
outcome after adjuvant chemotherapy (mainly FEC ± tax-
ane therapy) was investigated using invasive disease-free survival
(IDFS) as the primary clinical endpoint in 149 eligible SCAN-B
patients (Fig. 1). In both univariable Cox regression and
Kaplan–Meier analyses, BRCA1 hypermethylation alone or
combined with BRCA1-null cases was associated with sig-
nificantly longer IDFS than non-altered TNBC cases (Fig. 3f,
which also shows univariate results for standard prognostic
variables in breast cancer for reference and Fig. 3g). The 5-year
IDFS was 88% for BRCA1 hypermethylated patients versus 71%
for non-methylated TNBC patients, while the 5-year distant
relapse-free interval (DRFI) was 92% versus 80%, respectively. No
difference in IDFS after adjuvant chemotherapy was observed
between BRCA1 hypermethylated and BRCA1-null cases (Fig. 3g,
log-rank test, p= 0.29).
To assess the independent prognostic value after adjuvant
chemotherapy of BRCA1 hypermethylation alone or in combina-
tion with BRCA1-null status, we performed multivariable Cox
regression analysis adjusting for tumor size (≤20 mm, >20 mm),
patient age (<40, 40–59, and ≥60 years), tumor grade (2, 3), and
lymph node status (N0, N+) using IDFS as the clinical endpoint.
BRCA1 hypermethylation was significantly associated with
improved IDFS alone (HR= 0.33, 95% confidence interval (CI):
0.12–0.88) and when combined with BRCA1-null cases (HR=
0.35, 95% CI: 0.14–0.84), although the formal proportional
hazard assumption was not fulfilled in these analyses (propor-
tional hazard test, p < 0.05). When patient age was used as
continuous variable in the IDFS analyses the results were
borderline nonsignificant (Cox regression p= 0.07 for BRCA1
hypermethylation). Borderline nonsignificant results for BRCA1
hypermethylation versus non-methylated cases in multivariable
Cox regression using the above models with stratified age bins
(HR= 0.28, 95% CI: 0.08–1.02, p= 0.053) or continuous age
(Cox regression p= 0.09) were also observed for DRFI. A
significant association was seen for DRFI for the combined
hypermethylation/BRCA1-null group, irrespective of whether
binned age (HR= 0.23, 95% CI: 0.07–0.72) or continuous age
(HR= 0.32, 95% CI: 0.11–0.94) was used. For untreated or
neoadjuvantly treated SCAN-B patients the number of BRCA1
hypermethylated cases was too low to allow for robust outcome
analysis.
Genetic phenotypes of BRCA1 methylated and BRCA1-null
TNBC. To test the hypothesis that BRCA1 hypermethyla-
tion confers a similar genetic and genomic tumor phenotype as
BRCA1-null tumors we compared an array of readouts from
WGS between the two groups using the combined SCAN-B and
Nik-Zainal et al.24 cohorts (n= 57 hypermethylated and n= 52
BRCA1-null cases in total, Fig. 1).
The genome-wide landscape of copy number gain and loss
appeared highly similar between the two groups (Fig. 4a). A full
copy number analysis is available in Supplementary Fig. 4,
demonstrating no statistical differences between the groups (FDR
adjusted Fisher’s exact test, p > 0.05). Concerning specific breast
cancer driver genes/alterations reported by Nik-Zainal et al.24 we
observed some small frequency differences (typically < 5–10%,
when excluding MYC amplifications and TP53 mutations)
between the two groups regarding copy number amplifications
(Fig. 4b) and mutations (Fig. 4c). RB1 mutation status appeared
to show the largest difference between hypermethylated (n= 1/
57, 1.8%) and BRCA1-null (n= 4/52, 7.8%) cases for the
Fig. 2 BRCA1 hypermethylation, gene expression, and HRD association. a Hierarchical clustering (ward.D2 linkage, Euclidean distance) of DNA
methylation data (beta-values shown as a heatmap) for 30 CpGs associated with the BRCA1 gene (transcription start site (TSS): −1500b to +500 bp) in
Illumina MethylationEPIC data for 235 SCAN-B TNBCs, including 57 tumors classified as hypermethylated by pyrosequencing (black column sample
annotation bars). Gray CpG annotation bars (rows) indicate a promoter associated CpGs according to Illumina EPIC annotations. b BRCA1 mRNA
expression (FPKM) across the 237 SCAN-B cases stratified by gene abrogation status. p Values calculated using t-test. Top axis shows number of cases
per group. c Left: proportions of rearrangement signature 3 (RS3)24 versus patient stratifications based on BRCA1/2 mutation status, BRCA1 methylation
status, and BRCA1 LOH in the total SCAN-B cohort, excluding the small HRDetect-intermediate group. For non-BRCA1/2 cases, tumors are stratified by
HRDetect-high or low classification26. Right: proportion of deletions with microhomology across the same patient subgroups. Top axes show number of
cases per group. All cases do not have assigned RS3 rearrangements. d BRCA1 CpG allele methylation versus estimated tumor % by the WGS specific
Battenberg algorithm (https://github.com/cancerit/cgpBattenberg) for all 237 SCAN-B cases. Black dotted line corresponds to a linear regression fit for
the 57 hypermethylated cases specifically. e Circos plot and depiction of mutational substitution (S3, S8, and S13) and rearrangement signatures (RS2 and
RS3) as defined in ref. 24 of PD35990a. This case harbors both a BRCA2 variant and BRCA1 hypermethylation but has a genetic phenotype of BRCA1-
deficient cancer. Circos plot depicting from outermost rings heading inwards: karyotypic ideogram outermost. Base substitutions next, plotted as rainfall
plots (log10 intermutation distance on radial axis, Ring with short green lines, insertions; ring with short red lines, deletions. Major copy number allele ring
(green, gain), minor copy number allele ring (red, loss), Central lines represent rearrangements (green, tandem duplications; red, deletions; blue,
inversions; gray, interchromosomal events). FPKM fragments per kilobase of transcript per Million mapped reads. All p values reported from statistical
tests are two-sided. Source data are provided as a Source Data file.
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investigated specific driver alterations, albeit not significant
possibly due to low numbers (Fisher’s exact test, p= 0.19). A
high frequency of RB1 alterations, particularly intra-gene
rearrangements, has previously been linked with BRCA1-null
disease23. However, when considering all detected RB1 mutations
(i.e., not filtered for specific drivers), proportions were similar
between hypermethylated and BRCA1-null cases in the SCAN-B
cohort specifically (35 and 32%, respectively). Only a small
statistical difference in the number of indels (BRCA1-null:
median= 410, hypermethylated median= 633) was observed
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between the two groups for cases sequenced with at least 30-fold
sequence depth when comparing absolute numbers of substitu-
tions, indels and rearrangements between the two groups
(Fig. 4d). This absolute difference in numbers did, however, not
correspond to a difference in proportions of indels at repeats or
with microhomology, as previously shown (Fig. 2c). Moreover,
these results imply a similar tumor mutational burden for
hypermethylated and BRCA1-null cases.
For mutational signatures, BRCA1-null cases had higher
proportions of substitution signatures suggested to be associated
with age at diagnosis (Signatures 1 and 5), an APOBEC signature
(Signature 2), and, to some extent, a substitution signature
(Signature 8) reported to be elevated in cases with HRD27
(Fig. 4e). When tested for differential proportions in the
SCAN-B cases specifically (25 BRCA1-null versus 57 hyper-
methylated), only the specific APOBEC signature remained
elevated in BRCA1-null cases (Wilcoxon’s test, p= 1e−05),
driven by a subset (8/25 cases) of BRCA1-null cases with elevated
signature proportions. Strikingly, in hypermethylated cases no
substitutions were assigned to the particular APOBEC signature
(Signature 2), while many cases showed substitutions assigned to
another reported APOBEC signature (Signature 13). For
comparison, in non-basal tumors from Nik-Zainal et al.24 the
median APOBEC signature (Signature 2) proportions were
0.05–0.08 across PAM50 subtypes, with 7% of cases having no
signature exposure (Fig. 4e).
No distinct differences were seen for the six rearrangement
signatures reported by Nik-Zainal et al.24, including the two
BRCA1/BRCA2 associated signatures (RS3 and RS5) (Fig. 4f).
Hierarchical clustering and principal component analyses of
substitution and rearrangement signatures, or HRDetect26
components, did not separate hypermethylated from BRCA1-
null cases (Fig. 4g–i), supporting similar effects on DNA-repair.
DNA methylation in BRCA1 methylated and BRCA1-null
TNBC. To investigate differences in global DNA methylation
patterns between BRCA1-null and hypermethylated cases, Illu-
mina MethylationEPIC profiles from 25 BRCA1-null and 57
hypermethylated SCAN-B cases were compared. Preprocessing
and filtering left 614,977 informative CpGs sites. Supervised dif-
ferential methylation analysis between the groups identified
32 significant CpGs (false-discovery rate (FDR) adjusted Wil-
coxon’s test, p < 0.05). Strikingly, all 32 CpGs were associated
with BRCA1, with 28 CpGs within the canonical promoter region
(+500 to −1500 base pairs, chr17:43124984-43126983) and four
CpGs further upstream BRCA1 (chr17:43169746–43171745).
Cluster analysis based on the 32 CpGs recreated, as expected, the
division of BRCA1 hypermethylated versus non-methylated
tumors perfectly in the entire cohort of 235 DNA methylation
profiled cases (Fig. 5a).
Gene expression in BRCA1methylated and BRCA1-null TNBC.
Transcriptomic differences between BRCA1-null and BRCA1
hypermethylated cases were investigated in 52 BRCA1-null cases
versus 57 hypermethylated cases by combining SCAN-B cases
with 27 RNAseq analyzed BRCA1-null cases from Jönsson et al.23
(Fig. 1). Unsupervised clustering using 7224 highly varying genes
did not reveal any apparent subclusters specific for the two
sample groups (Fig. 5b). This finding was further substantiated by
both: (i) unsupervised consensus clustering using the same gene
set that showed similar proportions of BRCA1 hypermethylated
and BRCA1-null cases across different cluster solutions (Fig. 5c),
and (ii) principal component analysis showing that BRCA1
hypermethylation/BRCA1-null status, cohort (SCAN-B or non-
SCAN-B) or PAM50 subtypes did not contribute significantly to
explaining the variation in gene expression among these tumors
(Fig. 5d).
Differential gene expression analysis using significance analysis
of microarrays (SAM)32 between the groups was performed to
identify differentially expressed genes using the same 7224 genes
as for the cluster analyses. Merely eight genes, BRCA1, UQCRHL,
SOX6, HAPLN1, POLR2J3, H2AC20, MUCL1, and HYI, were
differentially expressed at a FDR of 1% (Supplementary Data 2).
Of these, BRCA1 (downregulated in hypermethylated cases, see
Fig. 2b), SOX6 (upregulated in hypermethylated cases), and
MUCL1 (downregulated in hypermethylated cases) showed
differential expression also in SCAN-B cases (Wilcoxon’s test, p
< 0.05), while HAPLN1 was borderline nonsignificant (Wilcox-
on’s test, p= 0.051) when analyzed separately (not accounting for
multiple testing). Taken together, the low number of differentially
expressed genes identified and the unsupervised analyses suggest
that there is no strong transcriptional difference between the
hypermethylated and BRCA1-null patient subgroups.
Immune infiltration in BRCA1 methylated and BRCA1-null
TNBC. In silico estimated immune cell composition in BRCA1
hypermethylated versus BRCA1-null cases was compared using
three different bulk tissue de-convolution methods based on
either gene expression (CIBERSORTx; 6 cell types33, xCell; 64 cell
types34) or DNA methylation (EpiDish; 9 cell types35) for the 82
hypermethylated or BRCA1-null SCAN-B cases. For neither of
Fig. 3 BRCA1 methylation in peripheral blood, gene expression subtypes, and prognosis after therapy. a Distribution of age at diagnosis for 43 germline
screened SCAN-B patients harboring germline BRCA1 loss of function variants (n= 9) or no germline variants (n= 34) further stratified by tumor BRCA1
hypermethylation status. b BRCA1 CpG allele methylation frequency in matched peripheral blood DNA from non-germline SCAN-B patients stratified by
their tumor methylation status (methylated= 1) from panel (a). c BRCA1 CpG allele methylation frequency in peripheral blood DNA from a combined
analysis of 105 SCAN-B cases analyzed using the same instrument settings and reagent lots, including 55 of 57 hypermethylated cases, and stratified by
patient age and tumor methylation status. Hard brackets ([]) imply ≥ or ≤, respectively. d Age at diagnosis for 237 SCAN-B patients stratified by BRCA1
and BRCA2 status. The number of methylated cases is less than 57 as two cases have concurrent BRCA2 mutations (one germline, one somatic
nonpathogenic). e Molecular subtype proportions in BRCA1 hypermethylated SCAN-B cases for PAM50, CIT, IntClust 10, and TNBCtype. CIT subtypes29;
mApo, molecular apocrine. IntClust 10 subtypes62; cluster 10 corresponding to basal-like tumors by other subtyping schemes. TNBCtype subtypes31; BL1,
basal-like 1: BL 2, basal-like 2: IM, immunomodulatory: M, mesenchymal: MSL, mesenchymal stem-like: LAR, luminal androgen receptor: UNC, uncertain.
f Univariate Cox regression using invasive disease-free survival (IDFS) as clinical endpoint for different variables in 149 SCAN-B patients eligible for
outcome analysis after standard of care adjuvant chemotherapy. HR: hazard ratio. NHG: grade, G2 equals grade 2, G3 equals grade 3. N0: node-negative.
A Zph p value < 0.05 corresponds to that the proportional hazard assumption is not fulfilled. An (n=) indication in the right axis indicates that not all 149
cases were used due to missing values. g Kaplan–Meier analysis using IDFS as clinical endpoint for SCAN-B patients eligible for outcome analysis after
adjuvant chemotherapy. Top panel shows the 149 patients stratified by BRCA1 hypermethylation status alone, center panel shows stratification including
also BRCA1-null cases, and bottom panel a comparison between only hypermethylated and BRCA1-null patients. All p values reported from statistical tests
are two-sided. Source data are provided as a Source Data file.
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the methods was a statistical difference in cell type proportions
observed between hypermethylated and BRCA1-null tumors for
any cell population (t-test, p > 0.05, data provided in Supple-
mentary Data 1). Supporting these observations, the expression of
102 immune cell type associated genes was analyzed by unsu-
pervised clustering and supervised differential gene expression in
the 82 SCAN-B cases. While groups of tumors displayed distinct
immune infiltration (e.g., consistent with the immune mod-
ulatory TNBCtype subtype) these were not defined by BRCA1-
status or PD-L1 immunohistochemistry status, nor was any gene
statistically different in expression between sample groups (FDR
adjusted Wilcoxon’s test p > 0.05) (Supplementary Fig. 5).
Next, PD-L1 immunohistochemistry scores (using the Roche
SP-142 antibody) were examined in 53 BRCA1 hypermethylated
and 25 BRCA1-null SCAN-B patients, finding no significant
difference in PD-L1 classification (≥1% staining in immune cells),
but a borderline nonsignificant trend of higher PD-L1 scores in
BRCA1-null cases (Wilcoxon’s test, p= 0.051, Fig. 6a). Presence
of TILs were evaluated on available whole slide H&E sections for
52 hypermethylated and 24 BRCA1-null SCAN-B cases, revealing
no significant difference between the groups (Wilcoxon’s test,
p= 0.70) (Fig. 6b).
To investigate whether PD-L1 differences between BRCA1-null
and hypermethylated cases were related to neoantigen burden, we
calculated number of expressed neoantigens from somatic
substitutions by integrating WGS-based HLA-typing, neoantigen
prediction, and mRNA expression for 232 of 237 SCAN-B
cases36,37. The Pearson correlation between the total substitution
burden and predicted number of expressed neoantigens from
substitutions was 0.91. PD-L1 positive cases (n= 120) had a
higher number of expressed neoantigens than PD-L1 negative
cases (n= 93) (Wilcoxon’s test, p= 0.02). In BRCA1-null and
hypermethylated cases there was however no statistical difference
(Wilcoxon’s test, p > 0.05) between the groups in total, or when
stratified by PD-L1 status, irrespective of whether all predicted
neoantigens were assessed (Fig. 6c, d) or weak or strong binders
were assessed separately36.
Discussion
DNA hypermethylation of promoter CpG islands is associated
with loss of gene expression and constitutes a long-known
mechanism of functional inactivation of tumor suppressor genes
in cancer cells. In the current study, we have comprehensively
analyzed the occurrence of BRCA1 promoter hypermethylation in
a population-based early-stage TNBC cohort, its readout on the
tumor genome and immune microenvironment, and its impli-
cations on patient outcomes after adjuvant standard che-
motherapy in the context of BRCA1-null tumors.
An important feature of our study is its population-based
nature with integrated tissue sampling in conjunction with rou-
tine diagnostics38, exemplified by the similar methylation rates
observed across individual years of patient enrollment. This lends
support to the reproducibility and generalizability of our results
in the context of the studied patient demographics for both
molecular and patient outcome findings, despite limited sample
numbers for some comparisons. In the total SCAN-B cohort,
24.1% of TNBC patients were BRCA1 hypermethylated, a pro-
portion in the lower to mid-range of previous reports14–20.
However, in comparison to the observed BRCA1-null rate of
10.5% among all SCAN-B patients, BRCA1 hypermethylation is
more than twice as frequent. Our analyses demonstrate a high
frequency of BRCA1 hypermethylation in young patients (46.2%
of TNBC patients less than 50 years). These women are often
referred to clinical germline BRCA-screening, which is increas-
ingly being considered for guiding the surgical procedure and
post-operative treatment39. Indeed, almost half of the women
who had undergone clinical BRCA1/2 sequencing without find-
ings of pathogenic germline variants had a tumor with BRCA1
hypermethylation. These women had no clear family history of
breast/ovarian cancer but had an age of diagnosis similar to
patients with germline BRCA1 alterations. Moreover, they had a
low but elevated level of BRCA1 promoter methylation also in
peripheral blood DNA, an observation confirmed in additional
clinically unscreened SCAN-B patients of varying age. Although
these results must be interpreted with caution as the hyper-
methylation levels are at the limit of detection by pyrosequencing
(and thus not suitable for prediction of somatic hypermethyla-
tion), they are intriguing in the context of both possible circu-
lating tumor DNA and findings of mosaic constitutional BRCA1
Table 2 BRCA1 promoter hypermethylation and BRCA1-null
frequency in TNBC.
BRCA1
hypermethylated
(n= 57)
BRCA1-null
(n= 25)a
BRCA1
non-altered
(n= 155)
Total SCAN-B cohort
(n= 237)b
24.1% 10.5% 65.4%
Primary disease only
(n= 231)
24.2% 10.4% 65.4%
Age
<50 years (n= 52) 46.2% 19.2% 34.6%
50–70 years (n= 108) 25.0% 12.0% 63.0%
≥70 years (n= 77) 7.8% 2.6% 89.6%
Tumor size
≤20mm (n= 120) 27.5% 10.8% 61.7%
>20mm (n= 117) 20.5% 10.3% 69.2%
Nodal status
Node negative (n= 153) 26.1% 7.8% 66.0%
Node positive (n= 81) 19.8% 14.8% 65.4%
Tumor grade
Grade 2 (n= 28) 0% 0% 100%
Grade 3 (n= 204) 27.5% 11.8% 60.8%
ER-staining positivity
<1% (n= 206) 24.8% 10.2% 65.0%
1–10% (n= 29) 20.7% 13.8% 65.5%
Adjuvant therapyc
Chemotherapy
(n= 149, IDFS)
28.9% 12.8% 58.4%
Untreated (n= 50) 12.0% 2.0% 86.0%
PAM50 subtypes61
Basal-like (n= 183) 30.1% 13.1% 56.8%
HER2-enriched (n= 31) 3.2% 3.2% 93.5%
Luminal A (n= 0) 0% 0% 0%
Luminal B (n= 1) 0% 0% 100%
Normal-like (n= 22) 4.5% 0% 95.5%
TNBC molecular subtypes63
Basal-like 1 (BL1, n= 46) 39.1% 13.0% 47.8%
Basal-like 2 (BL2, n= 23) 17.4% 8.7% 73.9%
Immunomodulatory (IM,
n= 46)
19.6% 13.0% 67.4%
Luminal androgen
receptor (LAR, n= 30)
0% 0% 100%
Mesenchymal (M, n= 41) 26.8% 12.2% 61.0%
Mesenchymal stem-like
(MSL, n= 14)
28.6% 7.1% 64.3%
IntClust 10 molecular subgroups62
10 (n= 148) 33.8% 12.2% 54.1%
9 (n= 13) 15.4% 15.4% 69.2%
4 (n= 57) 7.0% 5.3% 87.7%
1 (n= 2) 0% 0% 100%
3 (n= 5) 0% 0% 100%
5 (n= 2) 0% 0% 100%
8 (n= 1) 0% 0% 100%
CIT molecular subtypes29
Basal-like (basL, n= 175) 31.4% 12.0% 56.6%
Molecular apocrine
(mApo, n= 46)
2.2% 4.3% 93.5%
Luminal B (n= 1) 0% 0% 100%
Luminal C (n= 2) 0% 0% 100%
Normal-like (n= 4) 0% 0% 100%
Proportions calculated excluding missing data. Clinical data obtained from the Swedish national
breast cancer quality registry.
aBRCA1-null includes both germline and somatic cases.
bNumbers for each reported group are provided for reference.
cOnly includes cases eligible for outcome analysis by invasive disease-free survival (IDFS).
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hypermethylation. Regarding the latter, mosaic constitutional
BRCA1 hypermethylation has been reported in 4–7% of newborn
females40,41 as well as promoter methylation of BRCA1 or other
cancer-related genes in peripheral blood in women who devel-
oped TNBC or high grade serous ovarian cancer42–45 (see also
Tang et al.46 for review). Unfortunately, a lack of corresponding
fresh normal tissue hindered us from analyzing whether a mosaic
methylation pattern was present also in non-malignant breast
tissue. If elevated BRCA1 hypermethylation levels in blood cells
constitute a risk factor for TNBC (and ovarian cancer) develop-
ment and are present prior to tumorigenesis, these observations
raise important questions regarding potential screening, preven-
tion and early detection, requiring development of more sensitive
assays for patient classification. Irrespectively, our results
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implicate BRCA1 hypermethylation as the likely causative factor
underlying a significant proportion of women with TNBC, par-
ticularly in those without a family history of disease.
In agreement with previous studies19,23,24,47, BRCA1 hyper-
methylation was strongly associated with classical features of
BRCA1-null and basal-like disease. Despite this, BRCA1 promoter
hypermethylation was also present in subgroups such as old
patients and in molecular subtypes not commonly associated with
BRCA1 deficiency in TNBC, albeit at lower frequency. The latter
indicates that current gene expression phenotypes are not a
perfect surrogate for identification of BRCA1 deficiency. No case
of combined BRCA1 germline/somatic mutation and hyper-
methylation was observed, suggesting that these are separate
routes for gene inactivation and that loss of heterozygosity or
deletion of the wild type BRCA1 copy is the dominant second hit
in both hypermethylated and mutated cases. Moreover, the close
relationship between BRCA1 promoter allele methylation levels
and tumor cell content support a view that the hypermethylation
is already present in the main clone, as opposed to subclonal, and
therefore early in evolution of the tumor (Fig. 2d). While BRCA1
hypermethylation and germline/somatic mutations represent
separate mechanisms for gene inactivation, an objective of this
study was to explicitly and in detail test the hypothesis that these
alterations result in similar genomic phenotypes. Based on
comprehensive global genetic, gene expression, and DNA
methylation analyses we found support for this hypothesis.
BRCA1 hypermethylated cases share, with few exceptions, similar
frequencies of copy number alterations, proportions of reported
driver genes in breast cancer, tumor mutational burden, muta-
tional signatures, rearrangement signatures, gene expression
patterns, immune cell infiltration, and DNA methylation patterns
with BRCA1-null cases.
There are conflicting reports in the literature about whether
BRCA1 hypermethylation is associated with a better or worse
prognosis in early-stage disease (e.g., refs. 14–16,18,19,21). In
metastatic TNBC, BRCA1 hypermethylation has been reported
not to be associated with a better treatment response to carbo-
platin compared with docetaxel48 (although hypermethylation in
this study was measured in the primary tumor tissue, not the
actual metastatic tissue) or to single-agent carboplatin effect49.
This has led to a hypothesis of a soft/plastic BRCAness phenotype
for hypermethylated patients compared with germline BRCA1-
altered cases48, which remains to be proven by analysis of mat-
ched tissue from primary and relapsed tumors. Our survival
analyses show that BRCA1 promoter methylation appears as a
marker for favorable response to current conventional adjuvant
chemotherapy in early-stage TNBC, with a prognosis similar to
that of BRCA1-null cases. When considering the observed sur-
vival curves for hypermethylated cases and the typical early
relapse pattern of TNBC, the borderline nonsignificant statistical
findings for BRCA1 hypermethylation are likely due to a relatively
short follow-up time in the SCAN-B cohort (59% of cases have ≤5
years follow-up) and the limited sample size of the study. Simi-
larly, we saw significant or borderline nonsignificant patterns also
for other clinical endpoints like overall survival (OS) and DRFI.
Moreover, the observation of BRCA1 hypermethylation also in
old TNBC patients, often excluded from adjuvant therapy and
clinical trials, may warrant reconsideration in the clinical man-
agement of such patients. The explanation for the improved
prognosis of BRCA1 hypermethylated versus non-BRCA1 altered
cases may lie in the exclusive association with an HRD phenotype
as demonstrated in our prior study22. A growing body of evidence
suggests that TNBCs with an HRD phenotype (including non-
BRCA1/2 mutated cases with HRD inferred by other alterations)
respond better to DNA damaging agents3,13,22,50,51. In this con-
text, our observed high incidence of BRCA1 hypermethylation
implies that BRCA1 hypermethylation likely constitutes the most
common underlying cause of HRD in unselected early-stage
TNBC. Recent randomized clinical trial data in ovarian cancer
has showed that HRD-positive tumors without BRCA1/2 altera-
tions respond favorably to PARP-inhibitors as first-line main-
tenance therapy8. Similarly, advanced breast cancer patients with
HRDetect-high tumors have been shown to be associated with
clinical improvement on platinum-based chemotherapy50, sug-
gesting that also early stage patients with HRD-positive hyper-
methylated tumors may benefit from tailored therapies. If so, the
early stage patient cohort that could be considered for tailored
treatment would increase considerably, although the full treat-
ment effect remains to be determined in clinical trials.
TNBC tumors have been associated with high TIL-levels (sig-
naling immunogenicity) which are also prognostically
favorable52,53. A recent study has suggested a higher frequency of
TIL-positive tumors in BRCA1/2-mutated patients than in wild-
type cases54. In the SCAN-B cohort, TIL-levels did not differ
between hypermethylated and BRCA1-null cases, which is con-
sistent with the similar prognosis in these groups after adjuvant
chemotherapy. PD-L1 expression is also frequent in TNBC,
including BRCA1 hypermethylated tumors19, but studies have not
found that levels of PD-L1-positive TILs in TNBC cancers are
driven by a high mutation rate or by BRCA1 mutation status52,54.
This lack of association may now be appreciated through our
delineation of the BRCA1/2-wt subgroup by BRCA1 hyper-
methylation, forming a major subgroup of TNBC with similar
genetic and immune cell phenotypes as BRCA1-null cases. Taken
Fig. 4 Genetic phenotypes of BRCA1 hypermethylated and BRCA1-null TNBC. The 57 hypermethylated and 25 BRCA1-null SCAN-B cases were combined
with 27 BRCA1-null cases from Nik-Zainal et al.24. a Frequency of copy number alterations across the genome for BRCA1 hypermethylated and BRCA1-null
cases. b Frequency of copy number amplification for driver genes defined in Nik-Zainal et al.24. c Frequency of mutations (insertions, deletions,
substitutions) for driver genes defined in Nik-Zainal et al.24. Only genes with >1% alteration in the BRCA1-null cohort are shown. Displayed mutations in
BRCA1 are somatic. d Total number of substitutions, indels, and rearrangements per sample for BRCA1 hypermethylated versus BRCA1-null groups. Only
cases sequenced to at least 30-fold depth included. p Values calculated using Wilcoxon’s test. Top axes show number of cases per group. e Left panel
shows distribution of mutational signature (defined in Nik-Zainal et al.24) proportions per sample between hypermethylated versus BRCA1-null cases.
Proportions are calculated as the number of substitutions for a signature divided by the total number of substitutions from all signatures. Right panel shows
proportion of the APOBEC Substitution Signature 2 in non-basal-like tumors from Nik-Zainal et al.24. Top axis indicates number of samples per group. All
outliers are not shown due to y-axis scale. f Distribution of rearrangement signature24 proportions per sample between hypermethylated and BRCA1-null
cases. g Hierarchical clustering of combined substitution and rearrangement signature proportions using Pearson correlation and Ward.D linkage in the 109
combined cases. h Principal component analysis of proportions of substitution and rearrangement signatures in the 109 combined cases, illustrated by the
first two principal components representing most variation. i Principal component analysis of the proportions of the contributions of HRDetect components
(as defined in ref. 26) per sample (obtained from22), illustrated by the first two principal components representing most variation. The analysis only
included the 25 BRCA1-null and 57 hypermethylated SCAN-B cases. All p values reported from statistical tests are two-sided. Source data are provided as a
Source Data file.
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together, on a group level these results suggest that early-stage
hypermethylated cases may have similar response to immune
checkpoint inhibitors as the BRCA1-null group. Both groups are,
however, clearly heterogeneous and include both inflamed and
cold tumors with and without PD-L1 expression. Consequently,
the trend of higher PD-L1 levels in BRCA1-null tumors compared
with hypermethylated cases warrants further investigation, as
does the intersection between HRD-positivity and a variable
immunogenicity.
In summary, our analyses show that the genomic character-
istics of BRCA1 hypermethylated and BRCA1-null TNBCs are
highly similar, thus representing genomic phenocopies. This
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Source data are provided as a Source Data file.
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suggests that BRCA1 hypermethylation is an early event in tumor
development and that tumor progression proceeds along path-
ways common with BRCA1 germline mutated cases. TNBC
patients with BRCA1 hypermethylated tumors share a similar
beneficial outcome after standard of care adjuvant chemotherapy
as BRCA1-null patients, suggesting that BRCA1 hypermethylation
may represent a DNA based prognostic biomarker that is
detectable also in low-cellularity tumor tissue specimens. Whe-
ther BRCA1 hypermethylated early-stage TNBC patients respond
similar as BRCA1-null patients to platinum-based chemotherapy
regimens, PARP inhibitors, or immune checkpoint inhibitors
merits investigation. A key component in utilizing findings from
this study is to include methylation testing in routine clinical
diagnostics, requiring robust assays applicable to archival tissue to
be developed, and to develop sensitive assays for further inves-
tigation of hypermethylation patterns in peripheral blood and
their potential association with disease risk.
Methods
Ethics approval and consent to participate. Patients were enrolled in the Sweden
Cancerome Analysis Network—Breast (SCAN-B) study (ClinicalTrials.gov ID
NCT02306096)38,55,56, approved by the Regional Ethical Review Board in Lund,
Sweden (Registration numbers 2009/658, 2010/383, 2012/58, 2016/742, 2018/267,
and 2019/01252). All patients provided written informed consent prior to enroll-
ment. All analyses were performed in accordance with patient consent and ethical
regulations and decisions.
SCAN-B patient cohort. From our22 recently reported Swedish population
representative TNBC cohort (SCAN-B) of 237 patients we identified 57 BRCA1
hypermethylated cases based on pyrosequencing and 25 BRCA1-null cases by
WGS. All identified cases had complete WGS, RNA sequencing, global DNA
methylation profiles (performed for this study), and extensive clinical follow-up
data. A CONSORT diagram is provided in Supplementary Fig. 1. Clin-
icopathological characteristics for the 82 SCAN-B patients with genetic or epige-
netic BRCA1 alterations are summarized in Table 1 and detailed in Supplementary
Data 1. Of the 237 SCAN-B patients, 46 patients underwent clinical screening for
germline BRCA1 or BRCA2 alterations based on national guidelines at the time.
BRCA1 promoter hypermethylation analysis. BRCA1 pyrosequencing promoter
hypermethylation status was available from a prior study22 based on a protocol
reported by Saal et al.57. Briefly, the pyrosequencing assay involved analysis of two
CpG-dense amplicons containing five and four CpGs, respectively, with internal
controls for bisulfite treatment (nucleotide positions are relative to the +1 adenine
of the ATG translational start codon on the annotated Ensembl v36 BRCA1
genomic sequence): BRCA1 region 1, −1291 to −1267 (containing 5 CpGs); and
region 2, −1332 to −1310 (4 CpGs). The following primers were used:
BRCA1_Region1/2_PCR_F, 5′-NNTATTTTGAGAGGTTGTTGTT TAG-3′;
BRCA1_Region1/2_PCR_R, 5′-biotin-TAA AAAACCCCACAACCTATCC-3′;
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Fig. 6 Immune cell infiltration phenotypes in BRCA1-null and hypermethylated cases. a PD-L1 scoring of 53 BRCA1 hypermethylated and 25 BRCA1-null
SCAN-B cases using the Roche SP-142 antibody that is evaluated in immune cells. To the left, proportion of positive cases (≥1%), to the right distribution of
actual PD-L1 scores for the two groups. b Scoring of tumor infiltrating lymphocytes (TILs) in 52 BRCA1 hypermethylated and 24 BRCA1-null SCAN-B cases
based on available whole section H&E slides. c Total number of expressed neoantigens per sample as calculated from substitutions by NeoPredPipe36 for
BRCA1-null and BRCA1 hypermethylated SCAN-B cases. d Neoantigens as shown in (c), but stratified for sample groups also by PD-L1 IHC status. Four
hypermethylated cases did not have available PD-L1 immunohistochemistry data. All p values reported from statistical tests are two-sided. Source data are
provided as a Source Data file.
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BRCA1_Region1 _Seq, 5′-GAATTATAGATAAATTAAAA-3′; and BRCA1_R-
egion2_Seq, 5′-GGTAGTTTTTTGGTTT T-3′. CpGs covered by the assay include
cg16630982, cg15419295, cg16963062, cg20187250, cg04658354, cg04110421, and
cg21253966. Methylated and unmethylated controls were included in each bisulfite
conversion and pyrosequencing run. For the methylated control samples, across
ten pyrosequencing tumor runs, the mean and standard deviation for the per-
centage of BRCA1 allele methylation was 95.48 ± 1.22 for primer set 1 and 96.16 ±
1.32 for primer set 2. For the unmethylated control, the corresponding values were
2.68 ± 0.75 for primer set 1 and 1.55 ± 0.90 for primer set 2. The combined
methylation estimates for unmethylated samples (2.26 ± SD 0.45; max 3.59%) are
therefore in line with the estimates for the negative conversion controls. Taken
together, this demonstrates that the bisulfite conversion efficiency is sufficiently
high to ensure to avoid false-positive methylation results. A cut-off of 7% in allele
methylation was used to call samples as hypermethylated or not. The chosen cut-
off is between the highest methylation level of 3.6% for patients classified as
unmethylated (mean 2.3% and standard deviation 0.48%), and the lowest observed
methylation level of 13.6% for hypermethylated patients. Importantly, the 7% cut-
off is relevant for pyrosequencing data performed according to the specified pro-
tocol. It may therefore not be suitable for calling BRCA1 promoter hypermethy-
lation in Illumina Infinium Methylation beadchips.
In addition, pyrosequencing based BRCA1 hypermethylation analysis of blood
DNA for constitutional methylation was first performed for 34 of the 46 patients
that underwent clinical screening without germline BRCA1/2 findings. DNA from
matched blood samples were extracted using the Qiagen Midiprep kit according to
manufacturer’s instructions at the Labmedicin Skåne Biobank, Lund, Sweden.
Experiments were performed as a single batch experiment including bisulfite
conversion and pyrosequencing (Supplementary Methods). In a second analysis,
the original 34 patients were rerun together with 71 additional patients from the
SCAN-B cohort (n= 105 in total) covering in total 55 of the 57 included cases with
BRCA1 tumor hypermethylation. This second run was performed using the exact
same instrument settings, reagent lots, and PCR product amounts for all cases, but
using a separate bisulfite conversion for the 71 new cases.
Global epigenetic profiling. Global epigenetic profiling of BRCA1 hypermethylated
and BRCA1-null cases were performed using Illumina Infinium MethylationEPIC
beadchips (interrogating ~800,000 CpGs) according to manufacturer’s instructions at
the Center for Translational Genomics, Lund University and Clinical Genomics
Lund, SciLifeLab. Input DNA was the same as for WGS, extracted from tumor tissue
preserved in RNAlater (Qiagen, Hilden, Germany)38,55. Beadchip data analysis and
immune cell deconvolution based on DNA methylation data using EpiDISH with
Robust Partial Correlations (RPC)35 were performed as detailed I Supplementary
Methods. M-values were defined as log2(Beta/(1-Beta)) in line with58.
Gene-expression analyses. Gene-expression profiling was performed using RNA
sequencing (RNAseq) as outlined55, and data has been reported elsewhere as
Fragments Per Kilobase per Million reads (FPKM)59,60. Supervised and unsu-
pervised analyses were performed as outlined in Supplementary Methods. Mole-
cular subtype classification according to PAM5061, IntClust 1062, CIT29, and
reported TNBC subtypes (TNBCtype)31,63 were obtained from22. To increase the
number of BRCA1-null tumors in gene expression analyses for greater statistical
power we generated new RNA sequencing data (according to the same experi-
mental and data analysis protocol as for SCAN-B cases) from 27 ER- and PR-
negative BRCA1 germline cases reported originally by Jönsson et al.23. These were
added to the SCAN-B cases (n= 52 BRCA1-null cases in total). Immune cell
deconvolution was performed for RNAseq data using xCell34 and CIBERSORTx33
as outlined in Supplementary Methods.
Whole-genome sequencing analyses. Whole-genome sequencing data for
BRCA1 hypermethylated and BRCA1-null SCAN-B cases, including mutational
calls, mutational and rearrangement signatures, copy number profiles, and HRD
classifications (HRDetect26 and genomic scars, HRD-score13) were obtained from
ref. 22 (Supplementary Methods). Eighty-four percent of BRCA1-null and 82.5% of
BRCA1 hypermethylated cases were sequenced with a 30X target depth, while the
remaining cases were sequenced with a 15X target depth.
Expanded BRCA1-null whole genome sequencing cohort. To expand the
BRCA1-null cohort for analyses based on WGS data we used the reported cohort of
560 WGS analyzed breast cancers by Nik-Zainal et al.24. In this cohort, 27 TNBC
tumors were identified as germline BRCA1-null and added to the SCAN-B cases
(n= 52 BRCA1-null cases in total).
PD-L1 immunohistochemistry and TILs. PD-L1 immunohistochemistry using the
SP-142 antibody (Roche) was performed on a tissue microarray including 53
BRCA1 hypermethylated and 25 BRCA1-null SCAN-B tumors (two 1 mm cores/
tumor) on a Ventana instrument (Roche) according to manufacturer’s recom-
mendations. The SP-142 antibody is the intended PD-L1 test for atezolizumab
checkpoint inhibitor used in the Impassion 130 trial64. PD-L1 assessment was
performed according to antibody instructions on immune cells by a board certified
breast cancer pathologist, using a ≥1% cut-off for positivity. Negative cases in both
TMA cores were set to score 0.
TILs were scored on available whole section formalin-fixed paraffine embedded
haemotoxylin and eosin (H&E) slides by a board certified breast cancer pathologist
and summarized as a percentage per sample. Scoring was performed according to
the international consensus scoring recommendations of the International
Immuno-Oncology Biomarker Working Group on Breast Cancer (www.
tilsinbreastcancer.org). Scores were averaged when multiple slides were available
per patient. All pathology scorings were performed blinded to clinicopathological
and BRCA1 classifications.
Neoantigen prediction. NeoPredPipe36 was used to predict putative neoantigens
with substitution mutation calls provided by CaVEMan (https://cancerit.github.io/
CaVEMan/) and HLA typing done with Polysolver37 as input. hg19 was used as the
human reference genome throughout all analysis for the neoantigen predictions.
NeoPredPipe was run with default parameters except that options -c 1 2 -m where
set. Polysolver was run on WGS data from blood DNA with options: (i) unknown
ethnicity, (ii) use population-level allele frequencies as priors, and (iii) do not use
empirical insert size distribution. Only variants with a PASS flag in the variant call
file from CaVEMan was used as input to NeoPredPipe. Integration with RNAseq
expression was done as outlined for NeoPredPipe, and only neoantigens with an
expression >0.1 was kept for final analysis.
Statistical analyses. Survival analyses were performed in R (ver. 3.6.1) using the
survival package with OS, IDFS, or DRFI as endpoints defined according to the
STEEP guidelines65 (see Supplementary Methods for endpoint definitions and
analysis exclusion criteria). Survival curves were compared using Kaplan–Meier
estimates and the log-rank test. Hazard ratios were calculated through univariable
or multivariable Cox regression. Proportional hazard assumptions were tested
using the cox.zph function in the R survival package (ver. 3.1-12). Survival analyses
were performed using the 149 eligible cases (62.8%) from the total SCAN-B cohort
treated with standard-of-care adjuvant chemotherapy according to national
guidelines (in 96% of cases a FEC-based [combination of five fluorouracil, epir-
ubicin, and cyclophosphamide] treatment ± a taxane) to contrast BRCA1-deficient
groups versus non-altered patients. Full details on the exclusion criteria for out-
come analysis and individual patient treatment are available in Staaf et al.22. All
p values reported from statistical tests are two-sided if not otherwise specified. Box-
plot elements corresponds to: (i) center line=median, (ii) box limits= upper and
lower quartiles, (iii) whiskers= 1.5× interquartile range.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
For BRCA1 hypermethylated and BRCA1-null SCAN-B cases mapping of clinical and
molecular classifications to gene expression data GSE96058 [https://www.ncbi.nlm.nih.
gov/geo/query/acc.cgi?acc=GSE96058] is available in Supplementary Data 1. Illumina
DNA methylation data for BRCA1 hypermethylated and BRCA1-null SCAN-B cases is
available as GSE148748 [https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?
acc=GSE148748] at Gene Expression Omnibus. FPKM RNAseq data for the additional
27 BRCA1-mutated cases from Jönsson et al.23 is available in an online repository
associated with this study [https://doi.org/10.17632/2dbh285999.1]. Source data are
provided with this paper. The source data underlying Figs. 2a–d, 3a–d, 4a, 4d–g, 5a–d,
and 6a, b are provided as a Source Data file. Source data are provided with this paper.
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